Medizinische Universität Graz - Research portal
Selected Publication:
Groothuis, JR (Study group participant Resch, B) .
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.
Pediatr Infect Dis J. 2001; 20(6): 628-630.
Doi: 10.1097/00006454-200106000-00018
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Resch Bernhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- An Expanded Access Study was conducted to collect additional safety data on palivizumab. Preterm infants with or without bronchopulmonary dysplasia received palivizumab every 30 days during the respiratory syncytial virus season. Adverse events were low (6.9%) in the 565 subjects. Serious adverse events included hospitalization and 1 case of respiratory syncytial virus bronchiolitis not requiring hospitalization. This study reaffirms the safety and tolerability of palivizumab.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - administration and dosage
- Antiviral Agents - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Infant - administration and dosage
- Infant, Newborn - administration and dosage
- Infant, Premature, Diseases - prevention and control
- Injections, Intramuscular - prevention and control
- Male - prevention and control
- Respiratory Syncytial Virus Infections - prevention and control
- Treatment Outcome - prevention and control
- Find related publications in this database (Keywords)
- respiratory syncytial virus
- premature infants
- monoclonal antibodies
- bronchopulmonary dysplasia
- chronic lung disease
- respiratory disease
- infectious disease